MabSpace Starts US Trial of PD-L1 Drug; China Trial to Begin Soon

MabSpace Biosciences of Suzhou has dosed the first patient in a US Phase I trial of MSB2311, its second generation PD-L1 treatment for advanced solid tumors. It is the first MabSpace molecule to begin clinical trials. In China, MSB2311 is in the late stages of the CFDA review process, and MabSpace expects it will start a China Phase I trial soon. Using its proprietary platform MabSpace provides discovery services to other biopharmas and is also developing its own portfolio of six immuno-oncology antibodies, which are designed to work in combination with MSB2311. More details....

Share this with colleagues:

Original Article: MabSpace Starts US Trial of PD-L1 Drug; China Trial to Begin Soon

More From BioPortfolio on "MabSpace Starts US Trial of PD-L1 Drug; China Trial to Begin Soon"